



# COVID-19 VACCINES

## ISV VIRTUAL CONGRESS SERIES

1st Congress  
June 22, 2020

### Registration

[www.ISVCongress.org](http://www.ISVCongress.org)

#### CONTACT

PHONE:  
1-508-856-6791

EMAIL:  
[Info@ISVCONGRESS.ORG](mailto:Info@ISVCONGRESS.ORG)

### Program June 22, 9:00am – 12:00 noon (ET)

9:00 am Welcome and Introductions  
Chairs: Linda Klavinskis & Shan Lu, ISV

#### Opening Session (20 min talks + 5 min Q&A)

##### **Overview, Chair: Shan Lu, ISV**

9:05am Kwok-Yung Yuen, The University of Hong Kong  
Overview of COVID-19

9:30am Nick Jackson, CEPI  
Overview of COVID-19 vaccine development

#### Scientific Session One (18 min talks + 7 min Q&A)

##### **Nucleic Acid Vaccines, Chair: Margaret Liu, ISV**

9:55am Kate Broderick, Inovio Pharmaceuticals  
Advantages of a DNA-based Approach to the  
Development of a COVID-19 Vaccine

10:20am Barney Graham (VRC/NIAID/NIH)  
Rapid COVID-19 Vaccine Development Enabled  
by Prototype Pathogen Preparedness

##### **Viral Vector Vaccines, Chair: Linda Klavinskis, ISV**

10:45am Sarah Gilbert, University of Oxford  
Rapid Progress with Development of ChAdOx1  
nCoV-19

11:10am Tao Zhu, CanSino Biological  
Development of Adenovirus Vector based  
COVID-19 Vaccine

#### Scientific Session Two (25 min panel discussion)

##### **Challenges for COVID-19 vaccines development**

##### **Moderator: David Weiner, ISV**

11:35am Peter Openshaw, Imperial College London  
Stanley Perlman, University of Iowa  
Stanley Plotkin, VaxConsult

- Are human challenge studies acceptable?
- Safety concerns and suboptimal antibody responses

#### **Wrap up and announcement of 2<sup>nd</sup> ISV Virtual Congress on COVID-19 Vaccines**

12 noon Closing remarks  
Margaret Liu, ISV

The virtual congress will be run by Microsoft Teams.





# COVID-19 VACCINES

## ISV VIRTUAL CONGRESS SERIES

2nd Congress  
July 21, 2020

### Registration

[www.ISVCongress.org](http://www.ISVCongress.org)

#### CONTACT

PHONE:  
1-508-856-1179

EMAIL:  
[Info@ISVCongress.org](mailto:Info@ISVCongress.org)

#### **Program July 21, 9:00am – 12:00PM (ET)**

9:00 am Welcome and Introductions  
**Chair:** Shan Lu, UMass Medical School/ISV  
Linda Klavinskis, King's College London/ISV  
Introduction of ISV Virtual Congress

#### **Opening Session (20 min talks + 5 min Q&A)**

**Chair:** Denise Doolan, James Cook University/ISV  
9:05am Larry Corey, Fred Hutchinson Cancer Res. Center  
COVID Vaccine Planning: The USG Approach  
9:30am Marion Gruber, US FDA  
Regulatory Considerations in the Development  
and Licensure of COVID-19 Vaccines

#### **Scientific Session One (18 min talks + 7 min Q&A)**

##### **Part I: Protein and Inactivated Vaccines**

**Chair:** Manon Cox, NextWaveBio/ISV  
9:55am Greg Glenn, Novavax  
Progress with the Full Length Recombinant Spike  
Protein Nanoparticle Vaccine  
10:20am George Gao, China CDC  
Development of Inactivated COVID-19 Vaccines

##### **Part II: Viral Vector and RNA Vaccines**

**Chair:** Linda Klavinskis, King's College London/ISV  
10:45am Hanneke Schuitemaker, J&J/Janssen  
The Development of an Ad26-based  
SARS-CoV-2 Vaccine  
11:10am Kena Swanson, Pfizer  
RNA Based COVID-19 Vaccines

#### **Scientific Session Two (25 min panel discussion)**

##### **Challenges for COVID-19 Vaccines Development:**

##### **The Roles of Animal Models**

**Moderator:** Stanley Perlman, University of Iowa  
11:35am Bart Haagmans, Erasmus University  
Vincent Munster, RML/NIH  
Linda Saif, The Ohio State University

#### **Wrap up and Announcement of 3rd ISV Virtual Congress on COVID-19 Vaccines**

12:00PM Shan Lu, ISV

**ISV Virtual Congress Series Co-Chairs**  
Linda Klavinskis, Margaret Liu, Shan Lu / ISV  
**Senior Advisor**  
Nick Jackson / CEPI





## COVID-19 VACCINES

## ISV VIRTUAL CONGRESS SERIES

3rd Congress  
Aug 25, 2020

### Registration

[www.ISVCongress.org](http://www.ISVCongress.org)

#### CONTACT

PHONE:  
1-508-856-1179

EMAIL:  
[Info@ISVCongress.org](mailto:Info@ISVCongress.org)

### Program Aug 25, 9:00am – 12:00 noon (ET)

9:00 am Welcome and Introductions  
**Chair:** Shan Lu, UMass Medical School/ISV  
Linda Klavinskis, King's College London/ISV  
Introduction of ISV Virtual Congress

#### Opening Session (20 min talks + 5 min Q&A)

**Chair:** Shan Lu, ISV  
9:05am Myron Cohen, UNC-Chapel Hill  
mAbs for COVID-19: Treatment and Prevention  
9:30am Lynda Stuart, Bill & Melinda Gates Foundation  
COVID-19 Vaccine: How We Win the Race to  
Billions of Doses

#### Scientific Session One (18 min talks + 7 min Q&A)

##### **Part I: Protein Vaccines**

**Chair:** Xavier Saelens, University of Ghent/ISV  
9:55am Keith Chappell, The University of Queensland  
Molecular Clamp Stabilized Recombinant Protein  
Subunit Vaccine for COVID-19  
10:20am John Shiver, Sanofi-GSK  
Recombinant and mRNA Vaccine Candidates  
Against COVID-19

##### **Part II: Novel Vaccine Technologies**

**Chair:** Anna-Lise Williamson, University of Cape Town/ISV  
10:45am Jacqueline Miller, Moderna  
Moderna's Coronavirus Vaccine: Early Clinical Data  
and the COVE Phase III Efficacy and Safety Study  
11:05am Brian Ward, Medicago  
Development of Plant-Derived SARS-CoV-2 Virus-  
Like Particle (CoVLP) Vaccine

#### Scientific Session Two (30 min panel discussion)

The Role of T and B Cell Responses and Vaccine Assay Standards  
for Determining Efficacy  
**Moderator:** Margret Liu, ProTherImmune/ISV  
11:30am Alessandro Sette, La Jolla Institute for Immunology  
Michel Nussenzweig, The Rockefeller University  
Neil Almond, NIBSC

#### Wrap up and Future ISV Virtual Congresses

12:00pm Linda Klavinskis, ISV

#### ISV Virtual Congress Series Co-Chairs

Linda Klavinskis, Margaret Liu, Shan Lu / ISV  
**Senior Advisors**

Nick Jackson / CEPI, Susan Barnett / BMGF

